The pharmaceutical industry has become abundant with misuse and greed. Profit, shareholder returns and risk minimization are the primary goals for most stakeholders. Half of specialty drug spending is for cancer, rheumatoid arthritis, and multiple sclerosis. Saved lives and cured diseases are products of these primary objectives, but as a multi-trillion dollar money trail evolves, capitalism prevails. Predatory pricing is a major business strategy for many.
Click here to access the entire white paper.